Treatment of patients with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network by A. Aghemo et al.
17
Abstract. The arrival of potent directly acting 
antivirals (DAAs) for the treatment of chronic 
Hepatitis C virus (HCV) infection was a challen-
ge for the regional health system of the Lombar-
dia Region. Lombardia represents roughly 8% 
of the Italian territory but includes nearly 16% 
of the Italian population. In 2014, nearly 37,600 
HCV patients were routinely followed-up in li-
ver centers across the region; nearly 16,000 we-
re classified as having advanced fibrosis or cir-
rhosis (Metavir F3-F4). The creation of a regio-
nal network was necessary to ensure uniformi-
ty in treatment access and treatment manage-
ment. The first database analysis of the Lom-
bardia Hepatitis Network was conducted in Ja-
nuary 2016, and included data on 2432 patien-
ts who had received treatment from December 
2014 to December 2015. The most prevalent HCV 
genotypes were HCV-1 found in 63% and HCV-3 
found in 17%. Overall 90.4% patients achieved 
an SVR, SVR rates were 92.9% in HCV-1, 89.3% 
in HCV-2, 81.1% in HCV-3 and 88.9% in HCV-4.
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Background
The arrival of potent directly acting antivirals 
(DAAs) for the treatment of chronic Hepatitis C 
virus (HCV) infection was a challenge for the 
regional health system of the Lombardia Region1. 
Lombardia represents roughly 8% of the Italian 
territory but includes nearly 16% of the popu-
lation, which is mostly living in 3 macro-areas 
concentrated near Milan, Bergamo, and Brescia. 
To ensure that HCV patients were offered opti-
mal access to treatment with DAAs in the years 
2015-2016, at the end of 2014, the regional wel-
fare system conducted a survey among expert 
hepatology centers scattered throughout the re-
gion to understand the epidemiology of HCV in 
Lombardia and to assess the number of patients 
currently followed at Liver centers that fell into 
the National criteria for reimbursement of DAAs.
 
The Lombardia Hepatitis Network
In 2014 nearly 37,600 HCV patients were 
routinely followed-up in liver centers across the 
region, nearly 16,000 were classified as having 
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advanced fibrosis or cirrhosis (Metavir F3-F4). 
The next step was creating a network in the Lom-
bardia Region that could guarantee immediate 
access to therapy and state of the art clinical 
management to this large group of patients. Seven 
local experts on the management of chronic HCV 
were asked to provide standardized guidelines for 
treatment and management of viral hepatitis C as 
well as defining the required criteria to be labeled 
as a DAA prescribing center. 
Therapy recommendations were based on tho-
se provided by the Italian Association for the 
Study of the Liver (AISF), that regularly updates 
its treatment guidelines to follow those produced 
by the European Association for the Study of 
the Liver (EASL)2. The AISF guidelines take 
into account the Italian National Health system 
reimbursement rules when providing guidance 
on treatment options in Italy. The document 
produced by the local experts, defined Percorso 
Diagnostico Terapeutico Assistenziale (PDTA), 
did not only concentrate on treatment but also 
focused on diagnosis, management of patients 
with chronic HCV infection and outcome indi-
cators3. Although none of its recommendations 
were based on pharmaco-economy principles, 
every approved regimen for the treatment of 
chronic hepatitis C that was considered to be 
optimal by the experts was followed by the full 
price for the Regional health system to highlight 
differences in costs between similar treatment 
options. Liver centers included in the Regional 
Network for HCV were asked to follow the PDTA 
treatment recommendations and regularly provi-
de figures on treatment and sustained virological 
response (SVR) rates. Expert liver centers were 
required to have specific characteristics regarding 
the clinical know-how and cross-sectional exper-
tise (Table I). 
Table I. Characteristics that define an expert Liver Center.
Mandatory 1. A multi-disciplinary team including 
  an expert in liver diseases, a 
  pathologist and a dedicated nurse. 
  All experts need to have special 
  knowledge in viral hepatitis.
 2. A nominate Team cordinator 
 3. The nurse needs to have knowledge 
  in patients education and 
  managementof HCV patients 
 4. A local cohort of at least 500 patients 
 5. A local radiology unit
 6. A local Endoscopy unit 
 7. A local Laboratory capable of 
  performing virological test 
 8. A specialized outpatient unit 
 9. A local Pharmacy Unit 
 10. Link to a Regional Liver Transplant 
  Center 
Optional but  11. A multidisciplinary outpatient clinic
recommended  to diagnosis and manage patients
  with liver diseases 
 12. Proven clinical or translational 
  research activity on the field of viral 
  hepatitis 
 13. A link to a Virology Laboratory 
 14. A laboratory with expertise in 
  Drug Drug interactions
Figure 1. SVR rates in HCV-1 patients.
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The first database analysis was conducted in 
January 2016, and included data on 2432 patients 
who had received treatment in Lombardia from 
December 2014 to December 2015. Nearly ¾ of 
the enrolled patients (74%) fell in the number 
1 criteria for DAA reimbursement by AIFA, 
i.e., Child-Pugh A or B cirrhosis, while 14% of 
patients were classified as having F3 fibrosis. 
The most prevalent HCV genotypes were HCV-1 
found in 63% and HCV-3 found in 17%. At the 
time of analysis 1534 patients had completed the 
treatment phase and 872 could be evaluated for 
SVR. By ITT analysis overall 90.4% (788/872) 
patients achieved an SVR, SVR rates were 92.9% 
in HCV-1 (498/536), 89.3% in HCV-2 (101/113), 
81.1% in HCV-3 (116/143) and 88.9% in HCV-4 
(71/80). In HCV-1 patients, the SVR rates were 
largely dependent on the use of EASL/AISF ap-
proved treatment regimens as they ranged from 
98% with Paritaprevir/Ombitasvir/Dasabuvir ± 
Ribavirin to 79% in those who received the su-
boptimal combination of Sofosbuvir + Ribavirin 
(Figure 1). The same difference was seen in the 
overall cohort, since 93% of those who received 
an EASL/AISF endorsed regimen achieved an 
SVR compared to 87% of those who received 
suboptimal regimens (p=0.001). The use of su-
boptimal regimens was mostly dictated by ur-
gent cases that could not await the introduction 
of DAA combinations for HCV-3 and HCV-1 
decompensated patients, that were reimbursed 
in Italy only in the second quarter of 2015. This 
effect can be clearly seen when looking at the se-
cond update of the Lombardia Regional network 
which was performed in July 2016. In this case, 
more than 2293 patients were included in the 
SVR analysis. Overall 94.6% patients achieved 
an SVR, SVR rates were 97.4% in HCV-1a, 96.2 
in HCV-1b, 94.9% in HCV-2, 86.6% in HCV-3 
and 93.7% in HCV-4.
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